[Translation] A randomized, open-label, two-period, two-sequence, crossover bioequivalence study of toremifene citrate tablets in healthy adult subjects after single oral administration in the fasting state and after a high-fat meal

主要研究目的：研究重庆圣华曦药业股份有限公司生产的枸橼酸托瑞米芬片（规格：60mg）在中国健康受试者中空腹状态及高脂餐后以口服途径单次给药的药代动力学特征，并以 Orion Corporation 持有，Orion Corporation 生产的枸橼酸托瑞米芬片（商品名：法乐通®、FARESTON®；规格：60mg）为参比制剂，进行生物等效性评价。次要研究目的：初步考察枸橼酸托瑞米芬片受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Primary study objective: To study the pharmacokinetic characteristics of toremifene citrate tablets (specification: 60 mg) produced by Chongqing Shenghuaxi Pharmaceutical Co., Ltd. in healthy Chinese subjects in the fasting state and after a high-fat meal, and to evaluate the bioequivalence of toremifene citrate tablets (trade name: FARESTON®, FARESTON®; specification: 60 mg) owned by Orion Corporation and produced by Orion Corporation as the reference preparation. Secondary study objective: To preliminarily investigate the safety of the test preparation and reference preparation of toremifene citrate tablets in healthy subjects.

Start Date21 Dec 2023

Sponsor / Collaborator

Chongqing Shenghuaxi Pharmaceutical Co. Ltd.

CTR20232500 / CompletedNot Applicable

枸橼酸托瑞米芬片健康人体生物等效性研究

[Translation] Study on the bioequivalence of toremifene citrate tablets in healthy volunteers

主要目的：本研究以重庆士立德医药科技有限公司研发的枸橼酸托瑞米芬片（规格：60 mg）为受试制剂，按生物等效性研究的有关规定，以原研厂家Orion Corporation生产的枸橼酸托瑞米芬片（规格：60 mg，商品名：法乐通®）为参比制剂，评估受试制剂和参比制剂在空腹/餐后条件下给药后的生物等效性。次要目的：观察受试制剂枸橼酸托瑞米芬片和参比制剂枸橼酸托瑞米芬片（法乐通®）在健康受试者中的安全性。

[Translation]

Main purpose: This study used toremifene citrate tablets (specification: 60 mg) developed by Chongqing Shilide Pharmaceutical Technology Co., Ltd. as the test preparation. According to the relevant regulations of bioequivalence studies, toremifene citrate tablets (specification: 60 mg, trade name: Faleton®) produced by the original manufacturer Orion Corporation were used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting/postprandial conditions. Secondary purpose: To observe the safety of the test preparation toremifene citrate tablets and the reference preparation toremifene citrate tablets (Faleton®) in healthy subjects.

Start Date21 Aug 2023

Sponsor / Collaborator

Chongqing Shilide Pharmaceutical Technology Co., Ltd.

NCT05801705 / Not yet recruitingNot ApplicableIIT

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

This study aims to enroll premenopausal patients, with early breast cancer who are non-low-risk and hormone receptor-positive and have undergone prior surgical intervention at the Breast Cancer Center of Sun Yat-sen Memorial Hospital, Sun Yat-sen University. These participants, receiving tamoxifen (TAM), toremifene (TOR), or aromatase inhibitors (AI) as adjuvant endocrine therapy and undergoing ovarian function suppression (OFS) treatment, will be divided into three groups, namely TOR+OFS, TAM+OFS, AI+OFS. The study will compare the efficacy and safety of TOR+OFS to that of TAM+OFS or AI+OFS in premenopausal estrogen receptor-positive breast cancer patients by comparing the 5-year disease-free survival (DFS) and quality of life etc. The objective is to evaluate whether TOR+OFS is non-inferior to TAM+OFS or AI+OFS in this specific patient population.

Start Date01 Jun 2023

Sponsor / Collaborator

Sun Yat-Sen Memorial Hospital

100 Clinical Results associated with Toremifene Citrate

100 Translational Medicine associated with Toremifene Citrate

100 Patents (Medical) associated with Toremifene Citrate

717

Literatures (Medical) associated with Toremifene Citrate

15 Jan 2024·Cancer research and treatment

Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes

Article

Author: Li, Lin ; Li, Zhigao ; Zhang, Ming ; Qian, Cheng ; Ren, Yanlv ; Li, Zehao ; Wang, Jinsong ; Chen, Kejin ; Ji, Dongchen ; Li, Xin ; Liu, Tong

Purpose Tamoxifen showed individual differences in efficacy under different CYP2D6*10 genotypes. Our study evaluated the prognosis of tamoxifen or toremifene in hormone receptor (HR)–positive breast cancer patients under different genotypes.Materials and Methods CYP2D6*10 genotypes of HR-positive breast cancer patients were determined by Sanger sequencing, and all the patients were divided into tamoxifen group or toremifene group.Results A total of 268 patients with HR-positive breast cancer were studied. The median follow-up time was 72.0 months (range, 5.0 to 88.0 months). Of these, 88 (32.9%), 114 (42.5%), and 66 (24.6%) patients had C/C, C/T, and T/T genotypes, respectively. Among patients who received tamoxifen (n=176), the 5-year disease-free survival (DFS) rate in patients with C/C and C/T genotype was better than that in patients with T/T genotype, and the difference was statistically significant (p < 0.001 and p=0.030, respectively). In patients receiving toremifene, CYP2D6*10 genotype was not significantly associated with DFS (p=0.325). Regardless of genotypes, the 5-year DFS rate was higher in patients treated with toremifene than in patients with tamoxifen (91.3% vs. 80.0%, p=0.011). Compared with tamoxifen, toremifene remained an independent prognostic marker of DFS in multivariate analysis (hazard ratio, 0.422; p=0.021). For all the 180 patients with CYP2D6*10 C/T and T/T genotypes, the 5-year DFS rate was significantly higher in the toremifene group than in the tamoxifen group (90.8% vs. 70.1%, p=0.003).Conclusion Toremifene may be an alternative adjuvant endocrine therapy for patients with CYP2D6*10 mutant genotypes.

01 Jan 2024·Current medical imaging

Endometrial Adenofibroma in a Patient Receiving Toremifene: A Case Report

Author: Li, Tao ; Li, Lu ; Huang, Li-Zhao ; Liu, Gang

INTRODUCTION:

Adenofibroma is a rare benign Müllerian mixed tumor composed of epithelial and mesenchymal cells. This tumor may occasionally be associated with toremifene therapy which is used as an adjuvant drug for breast cancer.

CASE PRESENTATION:

We describe a case of a 55-year-old woman with adenofibroma of the endometrium. This patient was receiving toremifene after surgery and neoadjuvant chemotherapy for breast cancer. She underwent a total abdominal hysterectomy and bilateral salpingectomy. There was no evidence of tumor residual or recurrence at 32 months of MRI follow-up.

CONCLUSION:

In conclusion, we report a rare case of endometrial adenofibroma in a patient receiving toremifene. It must be borne in mind that long-term toremifene therapy may increase the frequency of endometrial neoplasms.

01 Dec 2023·Gan to kagaku ryoho. Cancer & chemotherapy

[Elderly Advanced Breast Cancer Effectively Treated with Locoregional Therapy-A Case Report].

Article

Author: Adachi, Keita ; Kubota, Hitomi ; Suzuki, Shuhei ; Hirano, Tomohiro ; Sakurai, Kenichi ; Nagae, Junko

We report a case of advanced breast cancer in an elderly patient effectively treated with locoregional therapy. The patient was an 81-year-old woman who presented with an increasing right breast lump. The tumor was 55 mm in diameter, accompanied by fixation to pectoral muscle. A core needle biopsy for right breast tumor led to a diagnosis of mucinous carcinoma, positive for estrogen receptor(ER)and progesterone receptor(PgR), negative for HER2/neu. The Ki-67 positive cell index was 10%. A bone scintigraphy revealed multiple bone metastases, so, we confirmed the diagnosis as T4cN2aM1, Stage Ⅳ. She initiated endocrine therapy by letrozole. By changing the endocrine therapy to toremifene followed by fulvestrant, the therapy achieved a partial response. However, the size of the primary tumor increased accompanied by bleeding, and surgical resection of the right breast was performed for local control. The locoregional surgery was effective, improving the patient's quality of life. She was administered lapatinib as anti-HER2 therapy in addition to the endocrine therapy. Two years and 6 months after surgery, there has been no worsening of bone metastasis or appearance of visceral metastasis.

News (Medical) associated with Toremifene Citrate

26 Oct 2021

·www.biospace.com

Adrenal Cortical Carcinoma Diagnosis and Treatment Market to Witness an Outstanding Growth by 2026

Adrenal cortex is the outer layer of the gland involved in production of lifesaving hormones such as mineralocorticoids and glucocorticoids (aldosterone and cortisol) required for metabolism and stress management. Adrenal glands are located on the top of the kidneys. Adrenal cortical carcinoma is the cancer of adrenal cortex. There are two types of tumor associated with adrenal cortex, such as functioning tumor and non-functioning tumor. Functioning tumor is responsible for increase in the production of adrenal hormones, whereas, non-functioning tumor does not affect hormonal production. Adrenal cortical carcinoma is generally a secondary type of cancer. It occurs when another form of cancer spreads into the adrenal glands. Request Brochure of Report - Increasing incidence of adrenal cortical carcinoma due to spread of other form of cancer, advancement in imaging technologies to identify adrenal cortical tumors specifically, growing healthcare expenditure, and rising number of cancer treatment centers across the world are some of the dominating factors expected to fuel the growth of the global adrenal cortical carcinoma diagnosis and treatment market during the forecast period. For instance, according to the Journal of Clinical Endocrinology & Metabolism, adrenal cortical carcinoma is a rare and highly aggressive malignancy. The incidence rate for adrenal cortical carcinoma is 0.7–2.0 cases per million people. The disease is more common in women. It is generally diagnosed in the age group of 40 and 50 years. However, high incidence of adrenal cortical carcinoma is recorded among children in Brazil due to the high prevalence of a specific TP53 germline mutation in them. Request for Custom Research - The global adrenal cortical carcinoma diagnosis and treatment market can be segmented based on type of test, type of therapy, end-user, and region. In terms of type of test used for the diagnosis of adrenal cortical carcinoma, the market can be divided into magnetic resonance imaging (MRI), computed tomography (CT) scan, positron emission tomography (PET) scan, and biopsy. In terms of type of therapy, the adrenal cortical carcinoma diagnosis and treatment market can be categorized into surgery, chemotherapy, other drug therapy, radiation therapy, and biologic therapy. The surgery therapy segment can be further categorized into laparoscopic surgeries and open surgeries. The chemotherapy segment can be classified based on the type of drug used for the treatment into mitotane and the combination therapy of cisplatin, doxorubicin (adriamycin), and etoposide (VP-16) plus mitotane. The other drug therapy segment involves treatment of hormonal effects caused by the tumor. Drugs included in this type of therapy are spironolactone, mifepristone, tamoxifen, toremifene, etc. The radiation therapy segment can be bifurcated into external beam radiation therapy and brachytherapy. In terms of end-user, the adrenal cortical carcinoma diagnosis and treatment market can be segmented into hospitals, specialty cancer clinics, diagnostic centers, and others. Pre Book Adrenal Cortical Carcinoma Diagnosis and Treatment Market Report at - Based on geography, the global adrenal cortical carcinoma diagnosis and treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the adrenal cortical carcinoma diagnosis and treatment market owing to high per capita disposable income and increasing incidence of the adrenal cortical carcinoma in the region. For instance, according to the American Cancer Society, adrenal tumors (most of which are benign adenomas) are found in 1 in every 10 people who undergo tests such as CT scan or MRI of the adrenal gland. Europe is expected to be the second leading market for semen analysis due to high awareness about early diagnosis and treatment of the disease, favorable reimbursement facilities, and increasing healthcare expenditure in the region. Asia Pacific can be considered as an emerging market for the diagnosis and treatment of adrenal cortical carcinoma. Key players operating in the global adrenal cortical carcinoma diagnosis and treatment market include HRA Pharma, ER Squibb & Sons LLC, Bristol-Myers Squibb Company, GE healthcare, WG Critical Care, LLC, David Bull Laboratories (Pty) Ltd., Mylan Pharmaceuticals, Fresenius Kabi, Pfizer, SINOVISION Technologies(Beijing) Co., Ltd., Hitachi Medical Systems, NeuroLogica Corp., and Digirad Corporation. More Trending Reports by Transparency Market Research: Smart Hospitals Market: The high prevalence of active COVID-19 (coronavirus) cases in the U.S., India, Brazil, and Russia has triggered innovations in humanoid robots. Stakeholders in the smart hospitals market are taking cues from Beijing-based robotics company CloudMinds, which is providing humanoid robots in hospitals to free up human medical staff and limit the possibility of virus spread. Nucleic Acid Extraction Instruments & Reagents Market: Food security and global health face a constant threat from various existing and new plant and human diseases that are primarily caused by fungi, viruses, and different types of pathogens. Over the past few decades, the outbreak of various diseases including swine flu, Ebola, SARS, MERS, and the most recent COVID-19 has led to considerable loss of human lives and hindered the growth of the economy in several regions. About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision. Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website:

Radiation Therapy

03 Aug 2006

·www.biospace.com

GTx, Inc. Announces Webcast Of Corporate Presentation At The Bank of America 2006 Specialty Pharmaceuticals Conference

MEMPHIS, Tenn., Aug. 3 /PRNewswire-FirstCall/ -- GTx, Inc. , the Men's Health Biotech Company, announced today that company management will present at the Bank of America Specialty Pharmaceuticals Conference at 1:30 p.m. Eastern time on August 10 at the Southampton Inn in Southampton, NY. The presentation will be simultaneously webcast. The link for the live webcast is . The presentation will also be accessible from the GTx website at . An archived replay of the presentation will be available until August 25, 2006. About GTx GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics for cancer and serious conditions related to men's health. GTx's lead drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones. GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. GTx is developing ostarine, a selective androgen receptor modulator, or SARM, for muscle wasting and bone loss indications. Ostarine is currently being evaluated in a Phase II clinical trial in 120 elderly men and postmenopausal women. GTx expects to have data from the Phase II ostarine trial in the fourth quarter of 2006. GTx has licensed to Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson, another of its SARMs, andarine, under a joint collaboration and license agreement. Forward-Looking Information is Subject to Risk and Uncertainty This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertainties. GTx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks that (i) GTx will not be able to commercialize its product candidates if clinical trials do not demonstrate safety and efficacy in humans; (ii) GTx may not able to obtain required regulatory approvals to commercialize its product candidates; (iii) GTx's clinical trials may not be completed on schedule, or at all, or may otherwise be suspended or terminated; and (iv) GTx could utilize its available cash resources sooner than it currently expects and may be unable to raise capital when needed, which would force GTx to delay, reduce or eliminate its product development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. GTx's quarterly report on form 10-Q filed with the U.S. Securities and Exchange Commission on May 5, 2006, contains a more comprehensive description of these and other risks to which GTx is subject. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. GTx, Inc. CONTACT: McDavid Stilwell of GTx, Inc., +1-901-237-9640 Web site:

Small molecular drug

15 May 2006

·www.biospace.com

GTx, Inc. To Be Added To The NASDAQ Biotechnology Index

MEMPHIS, Tenn., May 15 /PRNewswire-FirstCall/ -- GTx, Inc. , the Men's Health Biotech Company, announced today that it will be added to the NASDAQ Biotechnology Index(R) effective Monday, May 22, 2006. "GTx's addition to the Nasdaq Biotechnology Index will give the company increased visibility among investors as we focus our efforts on the commercialization of ACAPODENE for two important unmet medical needs in men's health and on the continued development of ostarine, a potential first-in-class drug," said Mitchell S. Steiner, M.D., Chief Executive Officer of GTx. The NASDAQ Biotechnology Index contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria, including market value, average daily share volume, and seasoning as a public company. About GTx, Inc. GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics for cancer and serious conditions related to men's health. GTx's lead drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones. GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. GTx also is developing ostarine, a selective androgen receptor modulator, or SARM, for a variety of indications including muscle wasting and bone loss in frail elderly patients, osteoporosis, muscle wasting in end stage renal disease patients, and severe burn wounds and associated muscle wasting. GTx has licensed to Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson, another of its SARMs, andarine, under a joint collaboration and license agreement. Forward-Looking Information is Subject to Risk and Uncertainty This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertainties. GTx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks that (i) GTx will not be able to commercialize its product candidates if clinical trials do not demonstrate safety and efficacy in humans; (ii) GTx may not be able to obtain required regulatory approvals to commercialize its product candidates; (iii) GTx's clinical trials may not be completed on schedule, or at all, or may otherwise be suspended or terminated; and (iv) GTx could utilize its available cash resources sooner than it currently expects and may be unable to raise capital when needed, which would force GTx to delay, reduce or eliminate its product development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. GTx's Quarterly Report on Form 10-Q filed on May 5, 2006 contains a more comprehensive description of these and other risks to which GTx is subject. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. GTx, Inc. CONTACT: McDavid Stilwell, Manager, Corporate Communications & FinancialAnalysis of GTx, Inc., +1-901-523-9700 Web site:

First in ClassSmall molecular drug

100 Deals associated with Toremifene Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D00967	Toremifene Citrate	L02BA02	DB00539

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Metastatic breast cancer	US	Kyowa Kirin Co., Ltd.	29 May 1997
Breast Cancer	JP	Orion Co., Ltd.	31 Mar 1995

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Precancerous Conditions	Phase 3	US	GTx, Inc.	01 Jan 2005
Precancerous Conditions	Phase 3	AR	GTx, Inc.	01 Jan 2005
Precancerous Conditions	Phase 3	CA	GTx, Inc.	01 Jan 2005
Prostatic Intraepithelial Neoplasia	Phase 3	US	GTx, Inc.	01 Jan 2005
Prostatic Intraepithelial Neoplasia	Phase 3	AR	GTx, Inc.	01 Jan 2005
Prostatic Intraepithelial Neoplasia	Phase 3	CA	GTx, Inc.	01 Jan 2005
Fractures, Bone	Phase 3	US	GTx, Inc.	01 Oct 2003
Fractures, Bone	Phase 3	MX	GTx, Inc.	01 Oct 2003
Osteoporosis	Phase 3	US	GTx, Inc.	01 Oct 2003
Osteoporosis	Phase 3	MX	GTx, Inc.	01 Oct 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00106691 (CTgov)	Phase 3	Prostatic Cancer \| Prostatic Intraepithelial Neoplasia \| Precancerous Conditions	1,589	Placebo	eecproodqt(cgsnibbxrw) = onxipxwvff icglntpstl (ensdewbexb, rotzuoqiax - afmchwehvp) View more	-	12 Jun 2023
NCT02344940 (Pubmed \| BMC Cancer)	Phase 4	Premenopausal breast cancer Adjuvant	92	Toremifene	ehryubchue(mbqwpdsjhz) = mneksgxpiq uryeuhmlkb (zbngllzxvs ) View more	-	16 Jul 2020
				Tamoxifen	ehryubchue(mbqwpdsjhz) = llznfzjlhj uryeuhmlkb (zbngllzxvs ) View more
NCT00106691 (Pubmed \| J Urol)	Phase 3	-	1,589	Toremifene citrate 20 mg	pcwhxxrylz(vbiwebthje) = vhqperjrwx elzosljvlj (cuoxidbfwm ) View more	-	10 Feb 2013
				Placebo	pcwhxxrylz(vbiwebthje) = hhmdxtrall elzosljvlj (cuoxidbfwm ) View more
NCT00129142 (Pubmed \| J Urol)	Phase 3	Prostatic Cancer	646	Toremifene	zjstatfwdb(aqtktxwkuv) = yqyiwfkdmo jvnmktoauj (fowmdduijn, -1.5 to 75.0) View more	Positive	01 Jan 2013
				Placebo	zjstatfwdb(aqtktxwkuv) = ibynbcerbb jvnmktoauj (fowmdduijn ) View more
ASCO2011	Not Applicable	Aggressive Fibromatosis	27	Toremifene	fyckmrkkpt(odxeyztyhh) = ckjxxfucdz znwgpwvsrh (pwojqxyemx ) View more	-	20 May 2011
ASCO2010	Phase 3	Fractures, Bone	-	Toremifene 80 mg	uairafprzz(trndapxhiz): relative risk reduction = 79.5 (95% CI, 29.8 - 94.0)	Positive	20 May 2010
				Placebo
863 (AUA2010)	Not Applicable	-	1,284	Toremifene 80mg	jnzfxoveol(rcyxkuayrw): OR = 0.59 (95% CI, 0.36 - 1.0), P-Value = <0.05	-	01 Apr 2010
				Placebo
ASCO2009	Phase 3	-	1,382	Toremifene citrate	xgrshqrkoy(nvnaclyced) = dntlfmxpet jdjloxstjs (eeqrvkkghf ) View more	-	20 May 2009
ASCO2005	Not Applicable	Breast Cancer	13	High-dose Toremifene	uzysgxayxe(gmioicwzdp) = ynymfjiinw plozimawty (jekqbahhqm ) View more	Positive	01 Jun 2005
ASCO2004	Phase 2	Breast Cancer Neoadjuvant	-	Toremifene (TOR)	mhsnrecpns(ridnsrpooh) = glhelnygaw jerveiwcja (exmeudjfzn, 28 - 58)	-	15 Jul 2004

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis